Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: A retrospective study

Transplantation

Volumn 79, Issue 8, 2005, Pages 964-968

  Birnbaum, Florian ^a   Böhringer, Daniel ^a   Sokolovska, Yevgenia ^b   Sundmacher, Rainer ^b   Reinhard, Thomas ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Cyclosporine A; High risk keratoplasty; Immunosuppression; Mycophenolate mofetil

Indexed keywords

CYCLOSPORIN A; FLUOCORTOLONE; FLUOCORTOLONE CAPROATE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISOLONE ACETATE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ATOPIC DERMATITIS; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; GINGIVA HYPERPLASIA; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPLAN MEIER METHOD; LIVER TOXICITY; MALE; PENETRATING KERATOPLASTY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SURGICAL RISK; SYSTEMIC THERAPY; TACHYCARDIA;

CYCLOSPORINE; DONOR SELECTION; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 17844371993     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000158022.62059.F2     Document Type: Article

References (30)

1. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989; 107: 506-510.
2. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology 1994; 101: 128-133.
3. Reinhard T, Hutmacher M, Sundmacher R. [Acute and chronic immune reactions after penetrating keratoplasty with normal immune risk]. Klin Monatsbl Augenheilkd 1997; 210: 139-143.
4. Sundmacher R. [Allograft rejection reactions after keratoplasty (author's transi)]. Klin Monatsbl Augenheilkd 1977; 171: 705-722.
5. Reinhard T, Sundmacher R, Godehardt E, et al. [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor]. Ophthalmologe 1997; 94: 496-500.
6. Reinhard T, Reis A, Bohringer D, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001; 239: 367-372.
7. Reis A, Reinhard T, Voiculescu A, et al. Mycophenolate mofetil versus cyclosporin A in high-risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 1999; 83: 1268-1271.
8. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321-1325.
9. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029-1037.
10. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999; 68: 391-396.
11. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63: 39-47.
12. Rose ML, Smith J, Dureau G, et al. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant 2002; 21: 282-285.
13. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450.
14. Reis A, Reinhard T, Sundmacher R, et al. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. Transplant Proc 1998; 30: 4344-4347.
15. Reis A, Reinhard T, Sundmacher R, et al. Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 1998; 82: 700-703.
16. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
17. Allison AC. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplant Proc 2002; 34: 2863-2866.
18. Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659-1662.
19. Reinhard T, Sundmacher R. [Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A - a retrospective study of 18 patients]. Klin Monatsbl Augenheilkd 1992; 201: 159-163.
20. Mayer K, Reinhard T, Reis A, et al. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 2003; 241: 1051-1054.
21. Reis A, Reinhard T, Voiculescu A, et al. [Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease]. Klin Monatsbl Augenheilkd 2001; 218: 183-186.
22. Sundmacher R, Stefansson A, Mackensen G. [Postoperative course after keratoplasty]. Fortschr Ophthalmol 1983; 80: 224-227.
23. Hoffmann F. [Suture technique for perforating keratoplasty (author's transi)]. Klin Monatsbl Augenheilkd 1976; 169: 584-590.
24. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981; 99: 599-604.
25. Pleyer U, Weidle EG, Lisch W, et al. [Clinical types of immunologic transplant reactions following perforating keratoplasty]. Fortschr Ophthalmol 1990; 87: 14-19.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
27. Girard LJ, Esnaolo N, Rao R. Allograft rejection after penetrating keratoplasty for keratoconus. Ophthalmic Surg 1993; 24: 40-43.
28. Tompson RW, Price MO, Bowers PJ, et al. Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003; 110: 1396-1402.
29. Reinhard T, Sundmacher R, Heering P. Systemic ciclosporin A in high-risk keratoplasties. Graefes Arch Clin Exp Ophthalmol 1996; 234 Suppl 1: S115-S121.
30. Reis A, Megahed M, Reinhard T, et al. Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 2000; 70: 1397-1401.